Leukadherin-1
Based on 6 publication(s) in Google Scholar
Leukadherin-1, a specific agonist of the leukocyte surface integrin CD11b/CD18, increases CD11b/CD18-dependent cell adhesion to fibrinogen with an EC50 of 4 μM. Leukadherin-1 enhances leukocyte adhesion to ligands (such as ICAM-1) and vascular endothelium and thus reduces leukocyte transendothelial migration and influx to the injury sites. Leukadherin-1 suppresses innate inflammatory signaling.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.0%
- CAS No.: 344897-95-6
- Formule: C22H15NO4S2
- Masse moléculaire:421.49
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Leukadherin-1
More
Customer Validation & Images
-
RT-PCR
-
Flow Cytometry
-
IF
Activité biologique
Leukadherin-1 is a specific agonist of the leukocyte surface integrin CD11b/CD18 (αMβ2; CR3; Mac-1). Leukadherin‐1 pretreatment reduces secretion of interferon (IFN)‐γ, tumour necrosis factor (TNF) and macrophage inflammatory protein (MIP)‐1β by monokine‐stimulated NK cells. Leukadherin‐1 pretreatment also reduces secretion of IL‐1β, IL‐6 and TNF by Toll‐like receptor (TLR)‐2 and TLR‐7/8‐stimulated monocytes[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Newborn Sprague Dawley rat pups[1]
-
Dosage:1 mg/kg
-
Administration:I.p.; twice daily for 14 days
-
Result:Beneficial on preventing the lung inflammatory response, improved alveolarization and vascular development, and reduced pulmonary vascular remodeling and PH in a hyperoxia-induced experimental model of BPD.
Chemical Information
-
CAS No. 344897-95-6
-
Appearance Solid
-
Masse moléculaire 421.49
-
Formule C22H15NO4S2
-
Color Yellow to orange
-
SMILES
O=C(O)C1=CC=C(C2=CC=C(/C=C(SC(N3CC4=CC=CC=C4)=S)/C3=O)O2)C=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
The ITGB2-COPS3-SOX2 Axis and SOX2 Liquid-Liquid Phase Separation: Dual Mechanisms Governing Osteosarcoma Stemness. [Abstract]2026 Mar 13:e20913. PMID: 41824786 -
ACS Environ Au
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]2025 Aug 5;5(6):573-582. PMID: 41277996 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Pharmaceuticals (Basel)
Altered Membrane Expression and Function of CD11b Play a Role in the Immunosuppressive Effects of Morphine on Macrophages at the Nanomolar Level. [Abstract]2023 Feb 13;16(2):282. PMID: 37259426
Leukadherin-1 purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2023 Feb 13;16(2):282. [Abstract]
RT-qPCR analysis of relative mRNA expression of anti-inflammatory and pro-inflammatory factors ARG1, PDGFB, IL6, STAT3 and MYC treated with Leukadherin-1 (LA1).
Leukadherin-1 purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2023 Feb 13;16(2):282. [Abstract]
Flow cytometry analysis of CD11b surface expression on macrophages treated with Leukadherin-1 (LA1) (4, 8 μM).
Leukadherin-1 purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2023 Feb 13;16(2):282. [Abstract]
Representative fluorescence photomicrographs of the phagocytic activity treated with Leukadherin-1 (LA1) (4, 8 μM).
-
Invest Ophthalmol Vis Sci
Microglial CD11b Knockout Contributes to Axonal Debris Clearance and Axonal Degradation Attenuation via IGF-1 After Acute Optic Nerve Injury. [Abstract]2023 May 1;64(5):7. PMID: 37145604 -
Solvant et solubilité
DMSO : 5 mg/mL (11.86 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (23.73 mM); Suspended solution; Need ultrasonic
Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 10 mg/mL (23.73 mM); Suspended solution; Need ultrasonic
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (597 KB)
- English - EN (597 KB)
- Français - FR (597 KB)
- Deutsch - DE (597 KB)
- Norwegian - NO (597 KB)
- Español - ES (597 KB)
- Swedish - SV (597 KB)
- Italian - IT (597 KB)
- Korean - KR (597 KB)
- Portuguese - PT (597 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Jagarapu J, et al. Efficacy of Leukadherin-1 in the Prevention of Hyperoxia-Induced Lung Injury in Neonatal Rats. Am J Respir Cell Mol Biol. 2015;53(6):793-801. [Content Brief]
[2]. Maiguel D, et al. Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease. Sci Signal. 2011;4(189):ra57. [Content Brief]
[3]. Roberts AL, et al. The complement receptor 3 (CD11b/CD18) agonist Leukadherin-1 suppresses human innate inflammatory signalling. Clin Exp Immunol. 2016;185(3):361-371. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3725 mL | 11.8627 mL | 23.7254 mL | 59.3134 mL |
| 5 mM | 0.4745 mL | 2.3725 mL | 4.7451 mL | 11.8627 mL | |
| 10 mM | 0.2373 mL | 1.1863 mL | 2.3725 mL | 5.9313 mL |
Leukadherin-1 Related Classifications
HY-15701 Related Classifications
Powered by Bioz